SCHEMBL5136239

SCHEMBL5136239

CCCCn1c(-c2ccccc2)nc(C(F)(F)F)c1CC(NCc1ccc(C(N)=O)cc1)c1ccc(OC(F)F)cc1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
PPARG P37231 1/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33
ADRB3 P13945 1/20 0.33
HAT1 O14929 2/20 0.33
EP300 Q09472 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
MDM2 Q00987 1/20 0.32
PTPN1 P18031 1/20 0.32
KDR P35968 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137318 0.94 PIN1 (0.36) HDAC1HDAC6ADRB3ALDH1A1HTT
SCHEMBL5135849 0.88 MDM2 (0.36) HDAC1HDAC6MDM2
SCHEMBL5138076 0.84 AGTR1 (0.36) HDAC1HDAC6
SCHEMBL651157 0.84 JAK2 (0.36) L3MBTL1PPARGJAK2JAK1TYK2
SCHEMBL5137484 0.82 PTGER4 (0.34) ALDH1A1
SCHEMBL5136020 0.79 PTGER4 (0.41) HDAC1PPARGALDH1A1
SCHEMBL5137377 0.79 PTGS2 (0.34) ADRB3
SCHEMBL651093 0.78 CRHR1 (0.37) PPARGJAK2JAK1TYK2JAK3
SCHEMBL648626 0.77 PIN1 (0.38) ALDH1A1HTTMDM2
SCHEMBL651310 0.77 NR1H4 (0.39) ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed